This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameAlatrofloxacin
Accession NumberDB09335
TypeSmall Molecule
GroupsWithdrawn
Description

Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Alatrofloxacin mesylate2IXX802851 157605-25-9CYETUYYEVKNSHZ-LGOOQLFJSA-NDetails
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII7QVV6I50DT
CAS number146961-76-4
WeightAverage: 558.518
Monoisotopic: 558.183852418
Chemical FormulaC26H25F3N6O5
InChI KeyUUZPPAMZDFLUHD-VUJLHGSVSA-N
InChI
InChI=1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1
IUPAC Name
7-[(1R,5S,6S)-6-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
SMILES
[H][[email protected]@]12CN(C[[email protected]]1([H])[[email protected]]2NC(=O)[[email protected]](C)NC(=O)[[email protected]](C)N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=CC=C(F)C=C1F)C(O)=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Alatrofloxacin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Alatrofloxacin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alatrofloxacin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Alatrofloxacin.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Alatrofloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Alatrofloxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Alatrofloxacin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alatrofloxacin.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Alatrofloxacin.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Alatrofloxacin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alatrofloxacin.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Alatrofloxacin.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0388 mg/mLALOGPS
logP0.65ALOGPS
logP-0.83ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)5.41ChemAxon
pKa (Strongest Basic)8.09ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area157.96 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity135.64 m3·mol-1ChemAxon
Polarizability52.84 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative ParentsNaphthyridine carboxylic acids and derivatives / Fluoroquinolones / Pyridinecarboxylic acids / Dialkylarylamines / Aminopyridines and derivatives / Fluorobenzenes / Piperidines / Aryl fluorides / Imidolactams / Vinylogous amides
SubstituentsAlpha peptide / Naphthyridine carboxylic acid / Fluoroquinolone / Diazanaphthalene / Naphthyridine / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Dialkylarylamine / Aminopyridine / Fluorobenzene
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Drug created on November 26, 2015 16:56 / Updated on September 01, 2017 12:04